2Doç. Dr., Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz, İstanbul, Türkiye
3Prof. Dr., Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz, İstanbul, Türkiye Purpose: To evaluate the outcomes of combined intravitreal ranibizumab (IVR) and posterior subtenon triamcinolone acetonide (STTA) injection for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Methods: Nineteen eyes of 19 patients with BRVO and cystoid ME were examined in this retrospective study. Nine eyes were treated with IVR and STTA, and afterwards with pro re nata (PRN) IVR (combined group) and 10 eyes received PRN IVR (control group). The outcome measures were: changes in the central macular thickness (CMT), best corrected visual acuity (BCVA), intraocular pressure (IOP), and number of injections.
Results: The mean initial CMT was 541±103?m in the combined and 475±57 ?m in the control group (p=0.14). The median baseline BCVA was 1.0 (0.60-1.15) LogMAR in the combined group and 0.75 (0.47-1.07) LogMAR in the control group (p=0.5). In both groups, CMT was signifi cantly reduced and BCVA was signifi cantly improved at the 1st and 3rd months and at the 1st year. In the fi rst 3 months, the combined group received a single dose, whereas the control group was treated with a median number of 2.5 (2-3) injections (p< 0.001). Nevertheless, the number of additional injections after the 1st injection wasn?t signifi cant between the groups [combined group: median 3 (1.5-3), control group: median 3 (1.75-4] p=0.34). No IOP elevations or other injection-related complications were encountered.
Conclusions: Combined IVR and STTA therapy seems to be comparable to IVR monotherapy in improving both CMT and BCVA in BRVO, with similar additional injection numbers.
Keywords : Ven tıkanıklığı, Ranibizumab, Subtenon triamsinolon